Medipharm Labs Corp(LABS-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0700
Day High0.0750
Open:0.0700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
GlobeNewswire
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
Baystreet
Stocks in play: MediPharm Labs Corp.
GlobeNewswire
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
GlobeNewswire
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
GlobeNewswire
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
Newsfile
Upcoming Meeting Dates - April 13, 2026
AllPennyStocks.com
International Medical Sales Surge 43% as GMP Certified Producer Hits Global Growth Phase
International Medical Sales Surge 43% as GMP Certified Producer Hits Global Growth Phase
GlobeNewswire
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
GlobeNewswire
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
GlobeNewswire
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
GlobeNewswire
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
GlobeNewswire
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
GlobeNewswire
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
GlobeNewswire
MediPharm Labs Completes First Shipment to France
GlobeNewswire
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
GlobeNewswire
MediPharm Labs Sets Date to Report Third Quarter 2025 Financial Results
Newswire.ca
MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees
Newswire.ca
/U P D A T E -- MediPharm Labs Corp./

Profile

MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.